Press Releases

MYOS RENS Technology Reports Fourth Quarter and Fiscal 2018 Results
MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Fiscal Year 2018 Results, Conference Call and Webcast
MYOS RENS Technology Announces Initiation of a Study at Kansas State University to Evaluate the Impact of Fortetropin® on Quality of Life and Activity in Geriatric Dogs
MYOS RENS Technology Announces First Endorsement Deal for Yolked® with NBA Superstar Aaron Gordon
MYOS CEO Joseph Mannello Issues Letter to Shareholders Following Presentation at North American Veterinary Community (NAVC) Conference/VMX
MYOS RENS Technology Announces Study Results Demonstrating Fortetropin®, the Active Ingredient in Myos Canine Muscle Formula, Prevents Muscle Loss in Canines After Surgery and Enhances Recovery
MYOS RENS Technology Announces Upcoming Presentation of Results from a Kansas State University Study Evaluating the Impact of Fortetropin® on Canine Muscle Loss after Surgery, at a Major Veterinary Conference, January 20, 2019
MYOS RENS Technology Receives a New Patent from the United States Patent and Trademark Office
MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders
MYOS RENS Technology Announces Results of Its 2018 Annual Meeting of Stockholders
RSS
Show All